StockData
Niagen Bioscience, Inc. logo

Niagen Bioscience, Inc. (NAGE) stock

NAGENasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3013% below fair value
$2.01−0.06 (-2.66%)

Close on Nov 16, 2026Market cap $159.04MP/E 16.8Yield –

Niagen Bioscience operating margin

Operating margin is operating income as a percentage of revenue.

Niagen Bioscience's operating margin for the twelve months ending Sep 30, 2026 was 3.9%. For fiscal 2025 it was 12.6%, against 7.8% the year before. The highest annual figure on record is 12.6% in fiscal 2025.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202512.6%+4.8
FY2024Dec 31, 20247.8%+14.5
FY2023Dec 31, 2023-6.7%+19.2
FY2022Dec 31, 2022-25.9%+14.3
FY2021Dec 31, 2021-40.1%−6.6
FY2020Dec 31, 2020-33.5%+34.1
FY2019Dec 31, 2019-67.6%+37.5
FY2018Dec 31, 2018-105.1%−27.9
FY2017Dec 30, 2017-77.2%−63.8
FY2016Dec 31, 2016-13.4%−1.9
FY2015Jan 2, 2016-11.6%+22.6
FY2014Jan 3, 2015-34.2%+9.0
FY2013Dec 28, 2013-43.2%+57.1
FY2012Dec 29, 2012-100.2%−3.3
FY2011Dec 31, 2011-96.9%−70.3
FY2010Jan 1, 2011-26.7%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 2026-5.8%−18.3
Q2 FY2026Jun 30, 20262.4%−7.9
Q1 FY2026Mar 31, 20265.0%−10.6
Q4 FY2025Dec 31, 202512.1%−12.3
Q3 FY2025Sep 30, 202512.5%+6.2
Q2 FY2025Jun 30, 202510.2%+11.4
Q1 FY2025Mar 31, 202515.7%+19.0
Q4 FY2024Dec 31, 202424.4%+25.2
Q3 FY2024Sep 30, 20246.3%+12.1
Q2 FY2024Jun 30, 2024-1.1%+10.3
Q1 FY2024Mar 31, 2024-3.3%+5.4
Q4 FY2023Dec 31, 2023-0.8%+6.1
Q3 FY2023Sep 30, 2023-5.9%+12.1
Q2 FY2023Jun 30, 2023-11.4%+26.8
Q1 FY2023Mar 31, 2023-8.7%+36.1
Q4 FY2022Dec 31, 2022-6.9%+23.1
Q3 FY2022Sep 30, 2022-18.0%+33.1
Q2 FY2022Jun 30, 2022-38.2%−6.8
Q1 FY2022Mar 31, 2022-44.8%+5.3
Q4 FY2021Dec 31, 2021-29.9%+9.4
Q3 FY2021Sep 30, 2021-51.1%−21.5
Q2 FY2021Jun 30, 2021-31.4%−7.3
Q1 FY2021Mar 31, 2021-50.1%−9.1
Q4 FY2020Dec 31, 2020-39.4%+28.3
Q3 FY2020Sep 30, 2020-29.6%+27.6
Q2 FY2020Jun 30, 2020-24.1%+40.6
Q1 FY2020Mar 31, 2020-41.1%+42.3
Q4 FY2019Dec 31, 2019-67.7%+23.2
Q3 FY2019Sep 30, 2019-57.1%+48.7
Q2 FY2019Jun 30, 2019-64.7%+37.0
Q1 FY2019Mar 31, 2019-83.3%+44.6
Q4 FY2018Dec 31, 2018-90.9%+25.7
Q3 FY2018Sep 30, 2018-105.9%−53.7
Q2 FY2018Jun 30, 2018-101.7%−52.9
Q1 FY2018Mar 31, 2018-127.9%−104.4
Q4 FY2017Dec 30, 2017-116.6%–
Q3 FY2017Sep 30, 2017-52.2%–
Q4 FY2016Dec 31, 2016-48.8%–
Q3 FY2016Oct 1, 2016-23.5%–

More Niagen Bioscience figures

See a number that looks wrong?